All In Biotech

Drug Trial Radar · NCT03742037

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 427 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

427

Actual

Start

Dec 21, 2018

Primary completion

Aug 31, 2021

Study completion Aug 25, 2022

Sponsor

Lead sponsor
Viatris Innovation GmbHIndustry
Sponsor type
Industry
First posted
Nov 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Cenerimod 0.5 mgDrug

    Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg

  • Cenerimod 1 mgDrug

    Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg

  • Cenerimod 2 mgDrug

    Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg

  • Cenerimod 4 mgDrug

    Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg

  • PlaceboDrug

    Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod

  • cenerimod 2 mg (ex-4 mg)Drug

    Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Month 6 in the Modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) ScoreTime frame: Baseline (Day 1) and Month 6

Locations

148 sites in 24 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group

    Anniston, Alabama

  • University of California San Diego

    La Jolla, California

  • Valerius Medical Group and Research Center

    Los Alamitos, California

  • University of Colorado School of Medicine

    Aurora, Colorado

  • Robert W Levin MD PA

    Clearwater, Florida

  • Center for Rheumatology Immunology and Arthritis

    Fort Lauderdale, Florida

  • Life Clinical Trials

    Margate, Florida

  • D&H National Research Centers INC

    Miami, Florida

  • San Marcus Research Clinic

    Miami Lakes, Florida

  • Millennium Research

    Ormond Beach, Florida

  • Integral Rheumatology & Immunology Specialists

    Plantation, Florida

  • Advanced Research Institute Inc Allergy & Rheumatology

    St. Petersburg, Florida

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • North Georgia Rheumatology Group - Duluth

    Lawrenceville, Georgia

  • Institute of Arthritis Research

    Idaho Falls, Idaho

  • Washington University School of Medicine

    St Louis, Missouri

  • Innovative Health Research

    Las Vegas, Nevada

  • New York Presbyterian Columbia University Medical Center

    New York, New York

  • State University of New York Upstate Medical University

    Syracuse, New York

  • Joint Muscle Medical Care and Research Institute - Lilington Office

    Charlotte, North Carolina

  • DJL Clinical Research

    Charlotte, North Carolina

  • Paramount Medical Research and Consulting

    Middleburg Heights, Ohio

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Office of Ramesh C. Gupta, MD

    Memphis, Tennessee

  • Amarillo Center for Clinical Research

    Amarillo, Texas

  • Accurate Clinical Research

    Houston, Texas

  • Southwest Rheumatology Research, LLC

    Mesquite, Texas

  • Sun Research Institute

    San Antonio, Texas

  • Accurate Clinical Management

    Stafford, Texas

  • University Multiprofile Hospital for Active Treatment Pulmed

    Plovdiv, Bulgaria

  • Diagnostic and Consulting Center "Aleksandrovska" EOOD

    Sofia, Bulgaria

  • Diagnostic Consulting Center Fokus-5

    Sofia, Bulgaria

  • Multiprofile Hospital For Active Treatment Trimontium

    Plovdiv, Plodiv, Bulgaria

  • Enroll SpA

    Santiago, Chile

  • Biomedica Research Group

    Santiago, Chile

  • Meditek Ltda.

    Santiago, Chile

  • Prosalud

    Santiago, Chile

  • Clinical Research Chile SpA

    Valdivia, Chile

  • CCR Pardubice

    Pardubice, Vychodocesky KRAJ, Czechia

  • Hôpital Haut-Lévêque

    Pessac, France

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.